Maintenance with sorafenib or midostaurin, even if not formally approved in all countries, demonstrated a survival advantage for patients with FLT-3-positive AML, when administered after allo-HCT, even if burdened with a certain degree of toxicity. The gene discussed is FLT3; the disease is acute myeloid leukemia.